Navigation Links
Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
Date:9/12/2007

Scientists at Childrens Hospital of Pittsburgh of UPMC have identified a potential target for the development of a vaccine against Chlamydia trachomatis, the most prevalent sexually transmitted bacterial infection in the world.

The researchers, led by Toni Darville, MD, chief of the Division of Pediatric Infectious Diseases at Childrens, identified a plasmid-deficient strain of Chlamydia that, when investigated in an animal model of genital tract infection, failed to cause disease. Plasmids are small molecules of DNA.

Results of their study are published in the Sept. 15 issue of the Journal of Immunology.

This finding represents a major step forward in our work to eventually develop a vaccine against chlamydial disease, said Dr. Darville, senior author of the study and also a professor of pediatrics and microbiology/immunology at the University of Pittsburgh School of Medicine. If we can identify plasmid-deficient derivatives of the C. trachomatis strains that infect humans, they would have the potential to serve as a vaccine against this disease.

Dr. Darville is considered one of the worlds foremost researchers of Chlamydia trachomatis, a bacterium which is the most frequently reported cause of sexually transmitted disease in the United States. Because symptoms are usually mild or absent, it can damage a womans reproductive organs and cause irreversible damage, including infertility, before a woman ever recognizes a problem.

In this study, a plasmid-deficient strain derived from Chlamydia muridarum was introduced to mice. The mice became infected but did not develop the trademark signs of chlamydial disease, particularly damage to the oviduct, the tube that carries eggs from the ovaries, according to Catherine M. OConnell, PhD, a researcher in Dr. Darvilles laboratory and first author of the study.

Not only did the mice not develop oviduct scarring after infection with the plasmid-deficient strain, we also found that the mice previously infected with these strains were protected against oviduct disease when later infected with fully virulent C. muridarum, Dr. OConnell said.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... , ... October 12, 2017 ... ... announces publication of a United States multicenter, prospective clinical study that demonstrates ... point-of-care diagnostic test capable of identifying clinically significant acute bacterial and viral ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
Breaking Biology Technology: